What Wickenstones does

Wickenstones is a privately held B2B consultancy founded in 2013 that delivers integrated evidence, access, commercial, and medical consultancy services to pharmaceutical and biotechnology clients. The firm operates from four offices—Oxford (UK headquarters), London (UK), Carlow (Republic of Ireland), and New York (USA)—with separate registered entities in England and Wales (No. 8576674), the Republic of Ireland (No. 651480), and the United States (No. 7411481). It serves clients across Europe and North America using a horizontal segmentation approach that spans multiple therapeutic areas, including oncology, cardio-renal, pulmonology, vaccines, gastrointestinal, immunology, neuro & CNS, neuromuscular, metabolic conditions, cell & gene therapy, medical devices & diagnostics, and radiology.

The company organises its offering around ten integrated capability areas: Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation (including real-world evidence), Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design. Services are delivered through dedicated, multidisciplinary teams wrapped around each client, with explicit commitments to bespoke solutions, proactive partnership, and consistent team continuity from pitch through delivery. The underlying "technology" is human expertise—primarily PhD- and MSc-level health economics, market access, and evidence generation professionals—rather than proprietary software platforms; no AI/ML capabilities, APIs, or productised tools are disclosed.

Wickenstones operates a professional services revenue model, generating revenue through project-based consulting engagements priced on a bespoke, quote-based structure tailored to each client's scope. Go-to-market is sales-led and direct enterprise engagement, with the firm relying on LinkedIn thought leadership, website case studies and publications, professional conferences such as ISPOR, and referrals for business development rather than digital storefronts or marketplaces. The firm has 11–50 employees, is founder-led by Eddie Gibson (CEO) with a CXO bench including Alysia Battersby (CTO), James Harris (COO), Dingeman Wolfert (Chief Client Officer), and Aidan Gough (CFO), and has not disclosed any external institutional investors, private equity backing, M&A activity, or public funding rounds.

Name

Wickenstones

Legal name

Wickenstones Limited

Website

https://wickenstones.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Wickenstones is a privately held pharma and biotech consultancy delivering integrated evidence, access, commercial, and medical services across ten capability areas—from HTA and pricing to RWE and value communications—for clients in the UK, EU, and US.

Ownership category

akta.pro rank

Headquarters

HQ city

Abingdon

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Consulting Services: Professional consulting services encompassing health technology assessment, global pricing, evidence generation, economic modelling, market research, value communications, route to market planning, stakeholder engagement, and organisational strategy and design. Revenue is generated through project-based consulting engagements with pharmaceutical and life sciences clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Wickenstones is a pharmaceutical and life sciences consultancy providing integrated evidence, access, commercial, and medical advisory services. It delivers ten capability areas — Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design — through dedicated, multidisciplinary teams wrapped around each client engagement.

Product overview

Wickenstones is a consultancy firm providing integrated evidence, access, commercial and medical consultancy services. The company offers ten distinct capability areas that work together as an integrated service offering: Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design. These services are delivered through dedicated multidisciplinary teams wrapped around each client, addressing complex challenges across market access, regulatory, medical, and commercial domains.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Technology Assessment Provides HTA landscape analyses, evidence mapping, global-local HTA strategies, and preparation for HTA interactions and early advice meetings to support payer decision-making across markets for pharmaceutical and biotech clients.
• Global Pricing Delivers evidence-based pricing solutions including global launch sequencing, early-stage pricing assessment, economically justifiable price modelling, and internal pricing frameworks to achieve market access and commercial success for pharmaceutical products.
• Evidence Review Conducts systematic literature reviews, systematised literature reviews, rapid reviews, and critical reviews to identify and synthesise evidence supporting regulatory and reimbursement objectives for pharmaceutical and biotech clients.
• Evidence Generation Plans and executes strategically focused real-world evidence (RWE) generation including cross-sectional studies, prospective studies, and retrospective studies to demonstrate product impact and address value proposition gaps for pharmaceutical clients.
• Economic Modelling Develops scientifically robust health economic models including cost-effectiveness models, budget impact models, capacity models, and decision analytic modelling to demonstrate product value and align with stakeholder needs.
• Market Research Delivers objective-driven market research providing deep insights into payer, HTA, HCP, and patient preferences through exploratory primary research, descriptive primary research, and market research review to guide market access strategy.
• Value Communications Crafts value narratives and develops tailored communication materials including global value dossiers, multi-channel communication materials, and animations aligned with stakeholder information needs.
• Route to Market Planning Develops commercialisation plans including investor planning, evidence planning, route-to-market planning, launch sequencing, and pre- and post-launch access strategy to maximise revenue through achievement of regulatory and access strategies.
• Stakeholder Engagement Provides stakeholder engagement strategy and activation planning, decision maker and influencer mapping, engagement tools, and stakeholder collaborations including evidence generation and event organisation.
• Organisational Strategy and Design Offers organisational design services including global, regional and local team reorganisation, process optimisation, governance and systems assessment, skills and capabilities evaluation, and external benchmarking.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Evidera (PPD): Dedicated HEOR, market access, real-world evidence, and HTA consultancy serving pharma and biotech — overlapping capability set across all ten of Wickenstones' service areas.
• Valid Insight (a Validant company): Pharma market access and pricing consultancy offering global pricing strategy, value communications, and stakeholder engagement — comparable capability footprint to Wickenstones.
• Putnam Associates: Strategy consulting firm focused on pharmaceutical and biotech clients, with deep market access, pricing, and HEOR expertise — directly comparable to Wickenstones' service offering.
• Maverex: Boutique pharma market access and HTA consultancy based in the UK, focused on payer engagement, submissions, and value communication — overlapping service mix with Wickenstones.
• Cytel: Statistical, HEOR, and real-world evidence consultancy serving pharma and biotech — provides market access, HTA support, and economic modelling services comparable to Wickenstones' capabilities.
• Mtech Access: UK-based market access, HTA, and HEOR consultancy with similar size and specialisation to Wickenstones, serving pharma clients across the UK and EU.

Broad incumbents

• IQVIA (Commercial & HEOR): Large-scale life sciences services and analytics provider with an established consulting and HEOR practice; competes for the same enterprise pharma market access and HTA engagements as Wickenstones but at significantly greater scale.
• Charles River Associates (Life Sciences): Global consulting firm with a life-sciences practice covering pricing, market access, and commercial strategy — competes for enterprise pharma strategy mandates with Wickenstones but at materially greater scale.
• McKinsey (Pharma & Medical): Global management consultancy with a dedicated pharma practice covering market access, launch strategy, and organisational design — broader portfolio but competes for top-tier strategic pharma mandates.

Others

• BIA (Bundesverband der Arzneimittel-Hersteller): German pharma industry association providing policy, market access, and HTA-related advisory support — adjacent to Wickenstones' HTA and stakeholder engagement capabilities in the European market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wickenstones-ltd
• Xx.com/wickenstones

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wickenstones